Cost-effectiveness of lenacapavir for PrEP in Africa

By sjmartinez • September 24, 2024

Davey DJ, Jamieson L. Cost-effectiveness of lenacapavir for PrEP in Africa. Lancet HIV. 2024 Sep 20:S2352-3018(24)00242-X. doi: 10.1016/S2352-3018(24)00242-X. Epub ahead of print. PMID: 39312934.

Tags: Infectious Diseases, Publications

Related Posts

Study design and procedures for a hybrid effectiveness-implementation incomplete stepped-wedge cluster-randomized trial to evaluate a differentiated point-of-care HIV diagnosis and management model for the prevention of vertical transmission of HIV in Malawi: The PAC-Man trial protocol

Herce ME, Cassidy C, Munson A, Edwards JK, Rutstein SE, Matoga M, Kumwenda C, Simon KR, van Oosterhout JJ, Cox CM, Kamanga F, Kumwenda W,[...]

Prevalence of chlamydial, gonococcal and syphilis positivity by anatomical site and sex via self-collected biospecimens using at-home testing kits among a large and diverse cohort of men and women enrolled in the MACS/WIHS Combined Cohort Study (MWCCS) in the USA

Mimiaga MJ, Tian J, Chiu I, Yonko EA, Noori G, Aziz N, Jamieson BD, Qian Y, Alcaide ML, Augenbraun M, Friedman MR, Kempf MC, Dionne-Odom[...]

Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort

Jayavelu ND, Qi J, Milliren CE, Ozonoff A, Liu S, Levy O, Baden LR, Melamed E, McComsey GA, Cairns CB, Schaenman J, Shaw AC, Hafler[...]